SPECT-CT Guided ELEctive Contralateral Neck Treatment (Select) for Patients with Lateralized Oropharyngeal Cancer.

Now open, the HN11 SELECT trial looking at a personalized radiotherapy treatment for throat cancer

CCTG HN11 SELECT has now opened to accrual across Canada and sites in the US. The trial is a randomized, controlled, phase III clinical trial for patients with lateralized oropharyngeal carcinoma (OPC)

More >>
CCTG PR24 ASCENDE-SBRT trial aims to treat prostate cancer

CCTG PR24 ASCENDE-SBRT trial aims to treat prostate cancer with improved precision

A new Canadian trial designed and led by Sunnybrook Health Sciences Centre will determine whether Stereotactic Ablative Body Radiotherapy (SABR) can replace the standard brachytherapy boost for men with unfavourable risk prostate cancer.

More >>
Three trials funded GU ASCENDE, IND241 SURELY, EN11 RAINBO-GREEN

CIHR SUCCESS with 7.5 million for three trials: GU ASCENDE, IND241 SURELY, EN11 RAINBO-GREEN

Three CCTG trials were recently awarded nearly $7.5M from the Canadian Institutes of Health Research (CIHR) 2022 Spring Project Grant competition.

More >>
Expansion of the Tissue Bank facilities

Expansion of the Tissue Bank facilities

The recently launched Centre for Health Innovation, aims to connect researchers from across multiple disciplines to tackle the most pressing human health challenges. A critical part of the centre will be a new home for the CCTG Tumour Tissue Data Repository and includes a large-scale expansion of its histopathology and biobanking resources.

More >>

Planned trials


MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML


Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials


Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)


Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)


RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial

More >>


Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma


Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)


CALMS: Combination Therapy with Luspatercept in Lower Risk MDS


Adjuvant Treatment Guided by Response Post Neoadjuvant Therapy for Stage III Melanoma


Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma


STOPNET - Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Med-Gut Tumours


Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment (ASCENDE-SBRT)


Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes


The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS


STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study

Recently activated


Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

More >>


Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)

More >>


A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

More >>


Liquid-Biopsy Monitoring for Patients not yet Eligible for Screening and Enrollment

More >>


Neoadjuvant Platform Trial in Surgically Resectable NSCLC

More >>


A Phase II Study of RP-6306 in Patients with Advanced Cancer

More >>


De-escalation of Chemo in HER-2+, ER-, Node-negative, breast cancer patients who achieved complete response after chemo and Dual HER-2 blOckade (DECRESCENDO)

More >>

Fighting a rare battle

Cancer is not a single disease; it is hundreds. Cancers of the lung, breast, prostate, and colon are the most common forms of the disease, and account for about half of all diagnoses. But less common forms of cancer also account for about half of diagnoses, and these are not as well studied.

More >>
The Impact of the COVID-19 on Canadians Living with Cancer

CCTG SC27 - The Impact of the COVID-19 on Canadians Living with Cancer

CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.

More >>
Britton Smith Foundation Clinical Trials Fund

Donation helps advance research

The establishment of the Britton Smith Foundation Clinical Trials Fund.  A thank you from Doug Kane, senior manager, Canadian Cancer Society FLA & The Waterways Community Office.

More >>

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>


Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients

Translational Lung Cancer Research 10: 826 - 838, 21 F
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;

More >>

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA)

J Clin Oncol 41: TPS259 - TPS259, 2023
Morris VK;Yothers G;Kopetz S;Jacobs SA;Lucas PC;Iqbal A;Boland PM;Deming DA;Scott AJ;Lim HJ;Hong TS;Wolmark N;George TJ;

More >>

NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US)

J Clin Oncol 41: TPS260 - TPS260, 2023
Lieu CH;Lin Y;Kopetz S;Jacobs SA;Lucas PC;Sahin IH;Deming DA;Philip PA;Hong TS;Rojas-Khalil Y;Loree JM;Wolmark N;Yothers G;George TJ;Dasari A;

More >>

Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials

J Clin Oncol 41: 124 - 124, 2023
Solar Vasconcelos JP;Chen N;Tu D;Brule SY;Goodwin RA;Jonker DJ;Price TJ;Zalcberg JR;Moore MJ;Karapetis CS;Siu LL;Shapiro JD;Simes J;O'Callaghan CJ;Loree JM;

More >>

Feasibility of circulating tumor DNA (ctDNA) to guide organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy, excision, and observation in the phase II CCTG CO.28 trial

J Clin Oncol 41: 180 - 180, 2023
Loree JM;Madison R;O'Callaghan CJ;Brown CJ;Tu D;Jonker DJ;Sherry M;Fine AD;Huang Y;Camara W;Pokharel P;Aleshin A;Oxnard GR;Kennecke HF;

More >>

Plasma phosphocreatine (PC) as a predictive biomarker for immune checkpoint inhibition in patients with refractory metastatic colorectal cancer (mCRC): Analysis of the CCTG CO.26 trial

J Clin Oncol 41: 183 - 183, 2023
Ma LX;Loree JM;Jonker DJ;Kennecke HF;Berry SR;Couture F;Ahmad CE;Goffin JR;Kavan P;Harb M;Colwell B;Samimi S;Samson B;Abbas T;Aucoin N;Aubin F;Koski SL;Tu D;O'Callaghan CJ;Chen EX;

More >>

INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)-A study led by the Australasian Gastro-intestinal Trials Group (AGITG)

J Clin Oncol 41: LBA294 - LBA294, 2023
Pavlakis N;Shitara K;Sjoquist KM;Martin AJ;Jaworski A;Yip S;Bang YJ;Alcindor T;O'Callaghan CJ;Tebbutt NC;Strickland A;Rha SY;Lee KW;Zalcberg JR;Price TJ;Simes J;Goldstein D;

More >>

Canadian Cancer Trials Group HE.1: A phase III study of palliative radiotherapy for symptomatic hepatocellular carcinoma and liver metastases

J Clin Oncol 41: LBA492 - LBA492, 2023
Dawson LA;Fairchild AM;Dennis K;Mahmud A;Stuckless TL;Vincent F;Roberge D;Follwell M;Wong RKW;Jonker DJ;Knox JJ;Zimmermann C;Wong P;Purdie T;Ringash J;Barry AS;Gaudet M;Tu D;Wong RK;O'Callaghan CJ;

More >>